› Forums › General Melanoma Community › CMP-001 has a new name and new trial in refractory stage 4 pd-1 patients
- This topic has 2 replies, 3 voices, and was last updated 3 years, 3 months ago by gopher38.
- Post
-
- May 31, 2021 at 9:26 am
Now called Vidutolimod, CMP-001 an injectable TLR-9 agonist opened up a trial for stage 4 patients who have progressed on Pd-1 drugs back in January. Here are a couple of links including trial information and company science explanation of how it turns cold tumors to hot tumors. https://www.onclive.com/view/vidutolimod-nivolumab-under-evaluation-in-pd-1-refractory-advanced-melanoma https://clinicaltrials.gov/ct2/show/NCT04698187 https://checkmatepharma.com/science/
Viewing 1 reply thread
- Replies
-
-
- May 31, 2021 at 10:49 am
Very interesting!!! Fingers and toes crossed for good results!If you haven’t heard about TLR (toll like receptor) agonists, they have been used in the form of SD101 and IMO-2125 (tilsotolimod) as intralesional therapy combined with systemic immunotherapy for folks with melanoma. The later combined with yervoy is addressed at point #2, with links to previous reports and background info within, in this post if you are interested: https://chaoticallypreciselifeloveandmelanoma.blogspot.com/search?q=tlr+agonist
Hopefully, in an intravenous form, TLR’s will bring new treatment options to melanoma peeps! Thanks, Edster! – c
-
Viewing 1 reply thread
- You must be logged in to reply to this topic.